메뉴 건너뛰기




Volumn 64, Issue 13 SUPPL., 2007, Pages

Pharmacist's role in managing anemia in patients with chronic kidney disease: Potential clinical and economic benefits

Author keywords

Anemia; Compliance; Continuous erythropoiesis receptor activator; Darbepoetin alfa; Diagnosis; Dialysis; Dosage schedules; Drug administration routes; Drug interactions; Economics; Hematopoietic agents; Iron; Iron preparations; Kidney diseases; Patient information

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

EID: 34347405959     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070183     Document Type: Conference Paper
Times cited : (24)

References (44)
  • 1
    • 34347388306 scopus 로고    scopus 로고
    • United States Renal Data System
    • Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006, accessed Feb 7
    • United States Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006. www.usrds.org/adr.htm (accessed 2007 Feb 7).
    • (2007) USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States
  • 2
    • 34347370550 scopus 로고    scopus 로고
    • National Institute of Diabetes and Digestive and Kidney Diseases. Kidney and urologic diseases statistics for the United States. kidney.niddk.nih.gov/ kudiseases/pubs/kustats/index.htm (accessed 2007 Feb 11).
    • National Institute of Diabetes and Digestive and Kidney Diseases. Kidney and urologic diseases statistics for the United States. kidney.niddk.nih.gov/ kudiseases/pubs/kustats/index.htm (accessed 2007 Feb 11).
  • 3
    • 45849155948 scopus 로고    scopus 로고
    • Estimating workforce and training requirements for nephrologists through the year 2010
    • Ad Hoc Committee on Nephrology Manpower Needs, May; , passim
    • Ad Hoc Committee on Nephrology Manpower Needs. Estimating workforce and training requirements for nephrologists through the year 2010. J Am Soc Nephrol. 1997 May; 8(5 suppl 9):S9-13, i-xxii, 1-32 passim.
    • (1997) J Am Soc Nephrol , vol.8 , Issue.5 SUPPL. 9
  • 4
    • 33646520143 scopus 로고    scopus 로고
    • Managing the burden of chronic kidney disease
    • Thorp ML, Eastman L, Smith DH et al. Managing the burden of chronic kidney disease. Dis Manag. 2006; 9:115-21.
    • (2006) Dis Manag , vol.9 , pp. 115-121
    • Thorp, M.L.1    Eastman, L.2    Smith, D.H.3
  • 5
    • 33751051945 scopus 로고    scopus 로고
    • Survey of care provided by ambulatory care pharmacists to patients with chronic kidney disease
    • Bennett RE, DeHart RM, Lauderdale SA. Survey of care provided by ambulatory care pharmacists to patients with chronic kidney disease. Am J Health-Syst Pharm. 2006; 63:2123-7.
    • (2006) Am J Health-Syst Pharm , vol.63 , pp. 2123-2127
    • Bennett, R.E.1    DeHart, R.M.2    Lauderdale, S.A.3
  • 6
    • 33646345152 scopus 로고    scopus 로고
    • KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease
    • National Kidney Foundation
    • National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(5 suppl 3):S11-145.
    • (2006) Am J Kidney Dis , vol.47 , Issue.5 SUPPL. 3
  • 7
    • 0036894205 scopus 로고    scopus 로고
    • Improving blood pressure control in a pharmacist-managed hypertension clinic
    • Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002; 22:1533-40.
    • (2002) Pharmacotherapy , vol.22 , pp. 1533-1540
    • Vivian, E.M.1
  • 8
    • 0035174174 scopus 로고    scopus 로고
    • Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic
    • Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy. 2001; 21:1337-44.
    • (2001) Pharmacotherapy , vol.21 , pp. 1337-1344
    • Okamoto, M.P.1    Nakahiro, R.K.2
  • 9
    • 1942503169 scopus 로고    scopus 로고
    • Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic
    • Cioffi ST, Caron MF, Kalus JS et al. Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. Ann Pharmacother. 2004; 38:771-5.
    • (2004) Ann Pharmacother , vol.38 , pp. 771-775
    • Cioffi, S.T.1    Caron, M.F.2    Kalus, J.S.3
  • 10
    • 33746333865 scopus 로고    scopus 로고
    • Development and clinical outcomes of pharmacist-managed diabetes care clinics
    • Morello CM, Zadvorny EB, Cording MA et al. Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health-Syst Pharm. 2006; 63:1325-31.
    • (2006) Am J Health-Syst Pharm , vol.63 , pp. 1325-1331
    • Morello, C.M.1    Zadvorny, E.B.2    Cording, M.A.3
  • 11
    • 33751040268 scopus 로고    scopus 로고
    • Outcomes of pharmacist-managed diabetes care services in a community health center
    • Scott DM, Boyd ST, Stephan M et al. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health-Syst Pharm. 2006; 63:2116-22.
    • (2006) Am J Health-Syst Pharm , vol.63 , pp. 2116-2122
    • Scott, D.M.1    Boyd, S.T.2    Stephan, M.3
  • 12
    • 0036828970 scopus 로고    scopus 로고
    • Establishing pharmaceutical services on a renal dialysis unit
    • Naughton CA. Establishing pharmaceutical services on a renal dialysis unit. Am J Health-Syst Pharm. 2002; 59:2111-2.
    • (2002) Am J Health-Syst Pharm , vol.59 , pp. 2111-2112
    • Naughton, C.A.1
  • 13
    • 22044451595 scopus 로고    scopus 로고
    • Impact of a pharmacist-implemented anemia management in outpatients with end-stage renal disease in Japan
    • Kimura T, Arai M, Masuda H et al. Impact of a pharmacist-implemented anemia management in outpatients with end-stage renal disease in Japan. Biol Pharm Bull. 2004; 27:1831-3.
    • (2004) Biol Pharm Bull , vol.27 , pp. 1831-1833
    • Kimura, T.1    Arai, M.2    Masuda, H.3
  • 14
    • 0031040828 scopus 로고    scopus 로고
    • Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist
    • Grabe DW, Low CL, Bailie GR et al. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol. 1997; 47:117-21.
    • (1997) Clin Nephrol , vol.47 , pp. 117-121
    • Grabe, D.W.1    Low, C.L.2    Bailie, G.R.3
  • 15
    • 3342936430 scopus 로고    scopus 로고
    • A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients
    • Viola RA, Abbott KC, Welch PG et al. A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients. BMC Nephrol. 2002; 3:9.
    • (2002) BMC Nephrol , vol.3 , pp. 9
    • Viola, R.A.1    Abbott, K.C.2    Welch, P.G.3
  • 16
    • 0032572913 scopus 로고    scopus 로고
    • The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    • Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:584-90.
    • (1998) N Engl J Med , vol.339 , pp. 584-590
    • Besarab, A.1    Bolton, W.K.2    Browne, J.K.3
  • 17
    • 27144498003 scopus 로고    scopus 로고
    • Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease
    • Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16:2180-9.
    • (2005) J Am Soc Nephrol , vol.16 , pp. 2180-2189
    • Parfrey, P.S.1    Foley, R.N.2    Wittreich, B.H.3
  • 18
    • 0035012513 scopus 로고    scopus 로고
    • The CREATE trial - building the evidence
    • Eckardt KU. The CREATE trial - building the evidence. Nephrol Dial Transplant. 2001; 16(suppl 2):16-8.
    • (2001) Nephrol Dial Transplant , vol.16 , Issue.SUPPL. 2 , pp. 16-18
    • Eckardt, K.U.1
  • 19
    • 33750983605 scopus 로고    scopus 로고
    • Correction of anemia with epoetin alfa in chronic kidney disease
    • Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-98.
    • (2006) N Engl J Med , vol.355 , pp. 2085-2098
    • Singh, A.K.1    Szczech, L.2    Tang, K.L.3
  • 20
    • 33751002326 scopus 로고    scopus 로고
    • Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    • Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355:2071-84.
    • (2006) N Engl J Med , vol.355 , pp. 2071-2084
    • Drüeke, T.B.1    Locatelli, F.2    Clyne, N.3
  • 21
    • 33751006109 scopus 로고    scopus 로고
    • Correction of anemia - payoffs and problems
    • Remuzzi G, Ingelfinger JR. Correction of anemia - payoffs and problems. N Engl J Med. 2006; 355:2144-6.
    • (2006) N Engl J Med , vol.355 , pp. 2144-2146
    • Remuzzi, G.1    Ingelfinger, J.R.2
  • 22
    • 23144442156 scopus 로고    scopus 로고
    • Extended epoetin alfa dosing in chronic kidney disease patients: A retrospective review
    • Germain M, Ram CV, Bhaduri S et al. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant. 2005; 20:2146-52.
    • (2005) Nephrol Dial Transplant , vol.20 , pp. 2146-2152
    • Germain, M.1    Ram, C.V.2    Bhaduri, S.3
  • 23
    • 23144460027 scopus 로고    scopus 로고
    • Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study
    • Provenzano R, Bhaduri S, Singh AK et al. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005; 64:113-23.
    • (2005) Clin Nephrol , vol.64 , pp. 113-123
    • Provenzano, R.1    Bhaduri, S.2    Singh, A.K.3
  • 24
    • 18744363354 scopus 로고    scopus 로고
    • Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease
    • Ling B, Walczyk M, Agarwal A et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005; 63:327-34.
    • (2005) Clin Nephrol , vol.63 , pp. 327-334
    • Ling, B.1    Walczyk, M.2    Agarwal, A.3
  • 25
    • 34347373168 scopus 로고    scopus 로고
    • Darbepoetin alfa (DbA) in patients (pts) with chronic kidney disease (CKD) once monthly (QM) clinical experience with SureClick
    • Presented at the San Diego, CA: November 14-19
    • Sousa A, Vinhas J. Darbepoetin alfa (DbA) in patients (pts) with chronic kidney disease (CKD) once monthly (QM) clinical experience with SureClick. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
    • (2006) American Society of Nephrology Annual Meeting and Scientific Exposition
    • Sousa, A.1    Vinhas, J.2
  • 26
    • 33750513406 scopus 로고    scopus 로고
    • Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis
    • Hoggard J, Crouch T, McMurray S et al. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin. 2006; 22:2023-30.
    • (2006) Curr Med Res Opin , vol.22 , pp. 2023-2030
    • Hoggard, J.1    Crouch, T.2    McMurray, S.3
  • 27
    • 34347373973 scopus 로고    scopus 로고
    • Outpatient RN + pharmacist-driven anemia clinic in stage 3-4 CKD: Efficacy and impact on disease progression
    • Presented at the San Diego, CA: November 14-19
    • Price M, Holdener K, Leverson G. Outpatient RN + pharmacist-driven anemia clinic in stage 3-4 CKD: efficacy and impact on disease progression. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
    • (2006) American Society of Nephrology Annual Meeting and Scientific Exposition
    • Price, M.1    Holdener, K.2    Leverson, G.3
  • 28
    • 2942746431 scopus 로고    scopus 로고
    • Anon. Section IV. Failure to respond to treatment. Nephrol Dial Transplant. 2004; 19(suppl 2):ii32-ii36. www.ndt-educational.org/images/ New%20EBPG%20Anaemia%20Part%20III.pdf (accessed 2007 Feb 11).
    • Anon. Section IV. Failure to respond to treatment. Nephrol Dial Transplant. 2004; 19(suppl 2):ii32-ii36. www.ndt-educational.org/images/ New%20EBPG%20Anaemia%20Part%20III.pdf (accessed 2007 Feb 11).
  • 29
    • 33750970834 scopus 로고    scopus 로고
    • Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: A randomised, multicentre, multiple-dose, phase II study
    • de Francisco AL, Sulowicz W, Klinger M et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006; 60:1687-96.
    • (2006) Int J Clin Pract , vol.60 , pp. 1687-1696
    • de Francisco, A.L.1    Sulowicz, W.2    Klinger, M.3
  • 30
    • 34347374577 scopus 로고    scopus 로고
    • CERA (continuous erythropoiesis receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every four weeks
    • Presented at the, St. Louis, MO: October 29-November 1, Abstract SU-PO051
    • Locatelli F, Villa G, Arias M et al. CERA (continuous erythropoiesis receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every four weeks. Presented at the 37th Annual Meeting and Scientific Exposition of the American Society of Nephrology, St. Louis, MO: October 29-November 1, 2004. Abstract SU-PO051.
    • (2004) 37th Annual Meeting and Scientific Exposition of the American Society of Nephrology
    • Locatelli, F.1    Villa, G.2    Arias, M.3
  • 31
    • 34347395454 scopus 로고    scopus 로고
    • CERA (continuous erythropoietin receptor activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race, or diabetic status
    • Presented at the Nashville, TN: April 2-5
    • Dutka P, Tilocca P. CERA (continuous erythropoietin receptor activator) maintains stable hemoglobin concentrations in dialysis patients irrespective of gender, age, race, or diabetic status. Presented at the American Nephrology Nurses' Association 37th National Symposium; Nashville, TN: April 2-5, 2006.
    • (2006) American Nephrology Nurses' Association 37th National Symposium
    • Dutka, P.1    Tilocca, P.2
  • 32
    • 33845630518 scopus 로고    scopus 로고
    • Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis
    • Provenzano R, Besarab A, Macdougall IC et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis. J Am Soc Nephrol. 2005; 16:760A.
    • (2005) J Am Soc Nephrol , vol.16
    • Provenzano, R.1    Besarab, A.2    Macdougall, I.C.3
  • 33
    • 34347404971 scopus 로고    scopus 로고
    • CERA administered at extended intervals corrects anemia and maintains stable Hbg levels in patients with CKD not on dialysis
    • Presented at the San Diego, CA: November 14-19
    • MacDougall C, Walker R, Provenzano R et al. CERA administered at extended intervals corrects anemia and maintains stable Hbg levels in patients with CKD not on dialysis. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
    • (2006) American Society of Nephrology Annual Meeting and Scientific Exposition
    • MacDougall, C.1    Walker, R.2    Provenzano, R.3
  • 34
    • 34347392188 scopus 로고    scopus 로고
    • Anemia management in pre-dialysis chronic kidney disease. A pharmacist-provided CKD anemia management clinic
    • Presented at the Las Vegas, NV: December 4
    • Joy M. Anemia management in pre-dialysis chronic kidney disease. A pharmacist-provided CKD anemia management clinic. Presented at the 40th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition; Las Vegas, NV: December 4, 2005.
    • (2005) 40th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition
    • Joy, M.1
  • 35
    • 0034918872 scopus 로고    scopus 로고
    • Management of patients with chronic renal insufficiency in the Northeastern United States
    • Kausz AT, Khan SS, Abichandani R et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001; 12:1501-7.
    • (2001) J Am Soc Nephrol , vol.12 , pp. 1501-1507
    • Kausz, A.T.1    Khan, S.S.2    Abichandani, R.3
  • 36
    • 34347405179 scopus 로고    scopus 로고
    • Iron preparations, oral
    • McEvoy GK, ed, Bethesda, MD: American Society of Health-System Pharmacists;
    • McEvoy GK, ed. Iron preparations, oral. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1410-7.
    • (2007) AHFS Drug Information 2007 , pp. 1410-1417
  • 39
    • 34347406833 scopus 로고    scopus 로고
    • Iron sucrose
    • McEvoy GK, ed, Bethesda, MD: American Society of Health-System Pharmacists;
    • McEvoy GK, ed. Iron sucrose. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1417-8.
    • (2007) AHFS Drug Information 2007 , pp. 1417-1418
  • 40
    • 34347383056 scopus 로고    scopus 로고
    • Venofer package insert. Shirley, NY: American Regent, Inc; October 2005
    • Venofer package insert. Shirley, NY: American Regent, Inc; October 2005.
  • 41
    • 34347392189 scopus 로고    scopus 로고
    • Sodium ferric gluconate
    • McEvoy GK, ed, Bethesda, MD: American Society of Health-System Pharmacists;
    • McEvoy GK, ed. Sodium ferric gluconate. In: AHFS Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1418-22.
    • (2007) AHFS Drug Information 2007 , pp. 1418-1422
  • 42
    • 34347381611 scopus 로고    scopus 로고
    • Ferrlecit package insert. Corona, CA: Watson Pharma, Inc. September 2006
    • Ferrlecit package insert. Corona, CA: Watson Pharma, Inc. September 2006.
  • 43
    • 33947212276 scopus 로고    scopus 로고
    • Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to i.v. iron with elevated ferritin (DRIVE) study
    • Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to i.v. iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007; 18:975-84.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 975-984
    • Coyne, D.W.1    Kapoian, T.2    Suki, W.3
  • 44
    • 34347398350 scopus 로고    scopus 로고
    • Outpatient erythropoietin administered via a protocol-driven pharmacist-overseen program is associated with significant patient and economic benefits
    • Presented at the San Diego, CA: November 14-19
    • Akers GR, Brown BL, Roberts SS et al. Outpatient erythropoietin administered via a protocol-driven pharmacist-overseen program is associated with significant patient and economic benefits. Presented at the American Society of Nephrology Annual Meeting and Scientific Exposition; San Diego, CA: November 14-19, 2006.
    • (2006) American Society of Nephrology Annual Meeting and Scientific Exposition
    • Akers, G.R.1    Brown, B.L.2    Roberts, S.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.